Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation
- PMID: 15822183
- DOI: 10.1146/annurev.pharmtox.45.120403.100045
Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation
Abstract
Cytochrome P450-catalyzed metabolism of arachidonic acid is an important pathway for the formation of paracrine and autocrine mediators of numerous biological effects. The omega-hydroxylation of arachidonic acid generates significant levels of 20-hydroxyeicosatetraenoic acid (20-HETE) in numerous tissues, particularly the vasculature and kidney tubules. Members of the cytochrome P450 4A and 4F families are the major omega-hydroxylases, and the substrate selectivity and regulation of these enzymes has been the subject of numerous studies. Altered expression and function of arachidonic acid omega-hydroxylases in models of hypertension, diabetes, inflammation, and pregnancy suggest that 20-HETE may be involved in the pathogenesis of these diseases. Our understanding of the biological significance of 20-HETE has been greatly aided by the development and characterization of selective and potent inhibitors of the arachidonic acid omega-hydroxylases. This review discusses the substrate selectivity and expression of arachidonic acid omega-hydroxylases, regulation of these enzymes during disease, and the application of enzyme inhibitors to study 20-HETE function.
Similar articles
-
Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11.J Pharmacol Exp Ther. 1998 Jun;285(3):1327-36. J Pharmacol Exp Ther. 1998. PMID: 9618440
-
Cloning, sequencing, and cDNA-directed expression of the rat renal CYP4A2: arachidonic acid omega-hydroxylation and 11,12-epoxidation by CYP4A2 protein.Arch Biochem Biophys. 1996 Dec 15;336(2):240-50. doi: 10.1006/abbi.1996.0554. Arch Biochem Biophys. 1996. PMID: 8954571
-
Catalytic activity and isoform-specific inhibition of rat cytochrome p450 4F enzymes.J Pharmacol Exp Ther. 2004 Mar;308(3):887-95. doi: 10.1124/jpet.103.059626. Epub 2003 Nov 21. J Pharmacol Exp Ther. 2004. PMID: 14634044
-
Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer.Adv Pharmacol. 2015;74:223-62. doi: 10.1016/bs.apha.2015.05.002. Epub 2015 Jun 27. Adv Pharmacol. 2015. PMID: 26233909 Free PMC article. Review.
-
Cytochrome P450 pathways of arachidonic acid metabolism.Curr Opin Lipidol. 2002 Jun;13(3):273-83. doi: 10.1097/00041433-200206000-00007. Curr Opin Lipidol. 2002. PMID: 12045397 Review.
Cited by
-
3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats.Br J Pharmacol. 2009 Dec;158(7):1808-19. doi: 10.1111/j.1476-5381.2009.00461.x. Br J Pharmacol. 2009. PMID: 19889059 Free PMC article.
-
Genetic polymorphisms in CYP4F2 may be associated with lung cancer risk among females and no-smoking Chinese population.Front Oncol. 2023 Mar 14;13:1114218. doi: 10.3389/fonc.2023.1114218. eCollection 2023. Front Oncol. 2023. PMID: 36998451 Free PMC article.
-
Contribution of 20-HETE to augmented myogenic constriction in coronary arteries of endothelial NO synthase knockout mice.Hypertension. 2005 Sep;46(3):607-13. doi: 10.1161/01.HYP.0000176745.04393.4d. Epub 2005 Jul 25. Hypertension. 2005. PMID: 16043660 Free PMC article.
-
Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury.Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):50-9. doi: 10.1016/j.prostaglandins.2006.05.017. Epub 2006 Jul 10. Prostaglandins Other Lipid Mediat. 2007. PMID: 17164132 Free PMC article. Review.
-
A convenient test system for the identification of CYP4V2 inhibitors.Mol Vis. 2021 Oct 6;27:601-607. eCollection 2021. Mol Vis. 2021. PMID: 34880593 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources